REG - GENinCode PLC - Grant of Share Options and PDMR dealing

GenincodeAnnouncement

17/09/2021 10:40

RNS Number : 1613M
  
GENinCode PLC
  
17 September 2021
  
 

 
17 September 2021
GENinCode Plc
("GENinCode" or the "Company") 
 
Grant of Share Options and PDMR dealing
 
GENinCode Plc (AIM:GENI), Oxford, UK, the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, announces today that the Remuneration Committee has recommended, and the Board has approved, to issue options over a total of 572,000 ordinary shares of £0.01 each in the capital of the Company ("Share Options").
 
The Share Options have been issued in line with the Company's existing share option plan to Paul Foulger, a director of the Company. The Share Options have been issued in addition to the existing options over ordinary shares granted to Paul Foulger on 15 April 2021 and combined, the number of ordinary shares held under option by Paul Foulger is 1,144,000, representing 1.19% of the existing issued ordinary share capital of the Company.
 
The Share Options are exercisable once the average market value of the Company's shares for a period of 30 consecutive dealing days following the date of the issue of the Share Options first exceeds two times the exercise price of £0.44.
 
 
Contacts: 
 




GENinCode plc


www.genincode.com 




Matthew Walls, CEO


Via Walbrook PR




Paul Foulger, CFO


 




 


 




Stifel Nicolaus Europe Limited (Nomad and Joint Broker)


Tel: +44 (0)20 7710 7600




Alex Price / Ben Maddison / Richard Short


 




 


 




Cenkos Securities Plc (Joint Broker)


Tel: +44 (0)20 7397 8900




Giles Balleny 


 




Dale Bellis / Michael Johnson (Sales)       


 




 


 




Walbrook PR Limited 


Tel: 020 7933 8780 or genincode@walbrookpr.com 




Anna Dunphy / Paul McManus / Louis Ashe-Jepson


 



 
 
 
 
 



 
About GENinCode plc
GENinCode plc (AIM: GENI) is engaged in the risk assessment, prediction and prevention of cardiovascular disease ("CVD"). CVD is the leading cause of death worldwide accounting for approximately 18 million deaths annually. The Company's products and technology have been developed with the aim of predicting the onset of CVD and providing a personalised treatment pathway for patient management. Its products have been the subject of clinical studies on over 75,000 patients to assess and predict the onset of CVD. 
 
The Company was incorporated in September 2018 to acquire the assets, intellectual property and know-how of the Ferrer inCode and Gendiag.exe businesses, which were then part of Grupo Ferrer Internacional S.A., a large Spanish multinational private pharmaceutical and healthcare company. The technology and products acquired included Cardio inCode®, Lipid inCode®, Thrombo inCode® and Sudd inCode®. The Directors believe that approximately €50 million has been invested in the research and development of these products since 2007. The Company has begun to commercialise these products in Europe and is now targeting the UK and US.
 
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:
 DIRECTOR/PDMR SHAREHOLDING




1


Details of the person discharging managerial responsibilities/person closely associated




a)


Name


Paul Foulger




2


Reason for the notification




a)


Position/status


CFO




b)


Initial notification/ Amendment


Initial Notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GENinCode Plc




b)


LEI


213800UX6TE7K65O2892




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument 
Identification code
 


Ordinary Shares of £0.01p
 
 
 

GB00BL97B504




b)


Nature of the transaction


Grant of conditional shares in the Company's Share Option Scheme




c)


Price(s) and volume(s)
 


 




Exercise Price


Volume




 £0.44


572,000




 




d)


Aggregated information
 - Aggregated volume
 - Price
 


 
 
N/A - single transaction




e)


Date of the transaction


 17 September 2021




f)


Place of the transaction


 Outside a trading venue




 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHSFLSUWEFSEDU